Using a Nebuliser Daily? It Could Lead to Advanced COPD

Nebuliser

therapy in those with an advanced stage of chronic obstructive pulmonary disease, or COPD, is most commonly used in those with more advanced stages of the disease, particularly those experiencing frequent exacerbations, high symptom burden, and reduced lung function. According to new long-term cohort data, this form of inhaled therapy for COPD is closely associated with disease severity rather than early or mild cases.

Understanding COPD and its progression

COPD is a progressive respiratory condition characterised by persistent airflow limitation, breathlessness, chronic cough, and recurrent flare-ups. Over time, symptoms worsen, often requiring more intensive treatment approaches. Managing COPD symptoms effectively is crucial to improving quality of life and reducing hospitalisations. The recent study followed nearly 3,000 participants over several years, including individuals diagnosed with COPD and tobacco-exposed individuals with preserved lung function. Researchers evaluated nebuliser use in COPD patients both at baseline and during follow-up to identify patterns of use in real-world clinical settings. The goal was to determine which patients are most likely to rely on nebuliser treatment and how its use correlates with disease progression.

Greater nebuliser use in advanced COPD

Findings revealed that nebuliser therapy is significantly more common in patients with advanced COPD. At baseline, nearly half of the individuals in the most severe disease category reported using a nebuliser. Most treatments involved short-acting bronchodilators, typically used on an as-needed basis to relieve acute symptoms such as breathlessness and wheezing.Also read: Not Just Genetics: 5 Heart Disease Myths Indians Must Stop Believing Today

Strong link between nebuliser use and disease severity

The study found a clear association between frequent nebuliser use and key indicators of severe COPD, including:

• Recent exacerbations or flare-ups
• Lower forced expiratory volume in one second (FEV1)
• Higher symptom burden and breathlessness scores
• Reduced exercise capacity
• History of asthma

These factors not only explained current nebuliser use but also predicted increased reliance on nebulisers over time. This suggests that nebuliser therapy in COPD is more reactive - used in response to worsening symptoms—rather than preventive.

Limited use of long-acting nebulised medications

Despite its frequent use in severe cases, the study highlighted that long-acting nebulised therapy remains underutilised. Most patients rely on short-acting medications for immediate relief, rather than incorporating nebulisers into long-term COPD maintenance therapy. This trend may indicate a gap in optimising treatment, especially for patients who struggle with handheld inhalers or require more consistent medication delivery.

Implications for COPD treatment strategies

The findings suggest that nebuliser use in COPD management is concentrated among patients with higher disease burden and frequent exacerbations. For healthcare providers, this raises important questions about whether current treatment strategies are fully aligned with patient needs. Optimising COPD treatment plans may involve:

• Evaluating inhaler technique and adherence
• Considering long-acting bronchodilators or combination therapies
• Exploring nebulised maintenance options for suitable patients
• Monitoring lung function and symptom progression regularly

The need for further research

Researchers emphasise the need for randomised controlled trials comparing nebulisers with handheld inhalers, particularly in patients with advanced COPD. Such studies could help clarify the role of nebulisers in long-term disease management and guide more personalised treatment approaches. In summary, nebuliser therapy in COPD is a strong indicator of disease severity and symptom burden. Rather than as a first-line treatment, it is most often used in response to worsenng respiratory function, highlighting the importance of early intervention and optimised care.